ND 003
Alternative Names: ND-003; ND003 - Shenzhen NewDEL BiotechLatest Information Update: 13 Jun 2024
At a glance
- Originator Shenzhen NewDEL Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-ret inhibitors; Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 09 May 2024 Shenzhen NewDEL Biotech initiates a phase I pharmacokinetics trial (In volunteers) in China (PO, Tablet) (NCT06360874)
- 10 Apr 2024 Shenzhen NewDEL Biotech plans phase I pharmacokinetics trial (In volunteers, In adults) (PO, Tablet) in April 2024 (NCT06360874)
- 04 Feb 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT06169579)